These data, summarized in Figure 5c,d, identified a trend (P ≤ .08) toward decreased HABP with VEGF overexpression in viable tumor regions (Figure 5c), and a significant decrease with VEGF overexpression in necrotic tumor regions (Figure 5d). The gene discussed is HABP2; the disease is neoplasm.